Who is sponsoring NCT03452722?

NCT03452722 is sponsored by University of Rijeka.

What drugs are being tested in NCT03452722?

Interventions in NCT03452722: intraventricual recombinant tissue plasminogen activator application.

What condition does NCT03452722 study?

NCT03452722 studies Hypertensive Intracerebral Hemorrhage, Intraventricular Hemorrhage, Brain Injuries.

Is NCT03452722 still recruiting?

NCT03452722 is currently completed. Last updated 26 March 2019.

Last reviewed 2019-03-26 · How we verify

NCT03452722

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Neuroinflammatory Response in Patients With ICH and IVH Treated With rtPA

Completed Last updated 26 March 2019

What this trial tests

trial testing intraventricual recombinant tissue plasminogen activator application in Hypertensive Intracerebral Hemorrhage in 88 participants. Completed in 1 September 2018.

Timeline

1 June 2011

Primary endpoint
1 August 2017

1 September 2018

Quick facts

Lead sponsor	University of Rijeka
Status	Completed
Study type	OBSERVATIONAL
Enrollment	88
Start date	1 June 2011
Primary completion	1 August 2017
Estimated completion	1 September 2018

Drugs / interventions tested

intraventricual recombinant tissue plasminogen activator application — full drug profile →

Conditions studied

Hypertensive Intracerebral Hemorrhage — all drugs for Hypertensive Intracerebral Hemorrhage →
Intraventricular Hemorrhage — all drugs for Intraventricular Hemorrhage →
Brain Injuries — all drugs for Brain Injuries →

Sponsor

University of Rijeka

Who can join

Adults 18 to 80, any sex, with Hypertensive Intracerebral Hemorrhage or Intraventricular Hemorrhage. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study compares the neuroinflammatory response in patients with hypertensive ICH associated with IVH treated with intraventriculary applied rtPA, and the control group. The inflammatory mediator concentration is analyzed in local cerebrospinal liquor.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other University of Rijeka trials

Trials by the same sponsor.

NCT07481422 — Safety and Efficacy of Lyophilized Faecal Microbiota Transplantation Via Capsules in Treatment of Irritable Bowel Syndro · Phase 1, PHASE2 · recruiting
NCT07431593 — Prognostic Value of SII and SIRI in Obesity-Related Metabolic Complications · not yet recruiting
NCT06925399 — Changes in Natural Immunity in Pregnant Women With Autoimmune Thyroid Disease · not yet recruiting
NCT05719519 — Change in Gingival Volume and Quality of Life Due to Initial Periodontal Therapy in Smokers · NA · unknown
NCT07170215 — Effect of Anti-gravity Treadmill Training After Total Hip Arthroplasty · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03452722 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Rijeka
Last refreshed: 26 March 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03452722.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing